175 related articles for article (PubMed ID: 19074062)
41. Recent advances in understanding myelofibrosis and essential thrombocythemia.
Vainchenker W; Constantinescu SN; Plo I
F1000Res; 2016; 5():. PubMed ID: 27134742
[TBL] [Abstract][Full Text] [Related]
42. MPL W515L mutation in pediatric essential thrombocythemia.
Farruggia P; D'Angelo P; La Rosa M; Scibetta N; Santangelo G; Lo Bello A; Duner E; Randi ML; Putti MC; Santoro A
Pediatr Blood Cancer; 2013 Aug; 60(8):E52-4. PubMed ID: 23441089
[TBL] [Abstract][Full Text] [Related]
43. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
44. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
45. Myeloproliferative disorders.
Levine RL; Gilliland DG
Blood; 2008 Sep; 112(6):2190-8. PubMed ID: 18779404
[TBL] [Abstract][Full Text] [Related]
46. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
47. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.
Giona F; Teofili L; Moleti ML; Martini M; Palumbo G; Amendola A; Mazzucconi MG; Testi AM; Pignoloni P; Orlando SM; Capodimonti S; Nanni M; Leone G; Larocca LM; Foà R
Blood; 2012 Mar; 119(10):2219-27. PubMed ID: 22262773
[TBL] [Abstract][Full Text] [Related]
48. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
49. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
50. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
51. JAK-2 mutations and their relevance to myeloproliferative disease.
Levine RL; Gilliland DG
Curr Opin Hematol; 2007 Jan; 14(1):43-7. PubMed ID: 17133099
[TBL] [Abstract][Full Text] [Related]
52. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
[TBL] [Abstract][Full Text] [Related]
53. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
Li J; Kent DG; Godfrey AL; Manning H; Nangalia J; Aziz A; Chen E; Saeb-Parsy K; Fink J; Sneade R; Hamilton TL; Pask DC; Silber Y; Zhao X; Ghevaert C; Liu P; Green AR
Blood; 2014 May; 123(20):3139-51. PubMed ID: 24692758
[TBL] [Abstract][Full Text] [Related]
54. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
55. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
Levine RL; Wernig G
Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
[TBL] [Abstract][Full Text] [Related]
56. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.
Etheridge SL; Cosgrove ME; Sangkhae V; Corbo LM; Roh ME; Seeliger MA; Chan EL; Hitchcock IS
Blood; 2014 Feb; 123(7):1059-68. PubMed ID: 24381227
[TBL] [Abstract][Full Text] [Related]
57. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Wadleigh M; Tefferi A
Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
[TBL] [Abstract][Full Text] [Related]
58. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia.
Schafer AI
Blood; 2006 Jun; 107(11):4214-22. PubMed ID: 16484586
[TBL] [Abstract][Full Text] [Related]
59. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.
Girardot M; Pecquet C; Boukour S; Knoops L; Ferrant A; Vainchenker W; Giraudier S; Constantinescu SN
Blood; 2010 Jul; 116(3):437-45. PubMed ID: 20445018
[TBL] [Abstract][Full Text] [Related]
60. Spontaneous regression of essential thrombocythemia with MPL mutation on menopause.
Otsuka M; Hanada S; Arita K; Ohashi H
Int J Hematol; 2014; 99(5):668-70. PubMed ID: 24609764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
